These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38211986)

  • 1. [Research progress on anti-inflammatory effects of plant-derived cannabinoid type 2 receptor modulators].
    Lian CX; Hu SJ; Zhang QY; Zhao QM; Qin LP; Gong W
    Zhongguo Zhong Yao Za Zhi; 2023 Dec; 48(23):6294-6306. PubMed ID: 38211986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.
    Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabimimetic plants: are they new cannabinoidergic modulators?
    Kumar A; Premoli M; Aria F; Bonini SA; Maccarinelli G; Gianoncelli A; Memo M; Mastinu A
    Planta; 2019 Jun; 249(6):1681-1694. PubMed ID: 30877436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy.
    Szczesniak AM; Porter RF; Toguri JT; Borowska-Fielding J; Gebremeskel S; Siwakoti A; Johnston B; Lehmann C; Kelly ME
    Neuropharmacology; 2017 Feb; 113(Pt B):627-638. PubMed ID: 27569993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modern approaches to the development of synthetic cannabinoid receptor probes.
    Saldaña-Shumaker SL; Grenning AJ; Cunningham CW
    Pharmacol Biochem Behav; 2021 Apr; 203():173119. PubMed ID: 33508249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of
    Intranuovo F; Brunetti L; DelRe P; Mangiatordi GF; Stefanachi A; Laghezza A; Niso M; Leonetti F; Loiodice F; Ligresti A; Kostrzewa M; Brea J; Loza MI; Sotelo E; Saviano M; Colabufo NA; Riganti C; Abate C; Contino M
    J Med Chem; 2023 Jan; 66(1):235-250. PubMed ID: 36542836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells.
    Chiba T; Ueno S; Obara Y; Nakahata N
    J Pharm Pharmacol; 2011 May; 63(5):636-47. PubMed ID: 21492165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
    Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
    Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.
    Porter RF; Szczesniak AM; Toguri JT; Gebremeskel S; Johnston B; Lehmann C; Fingerle J; Rothenhäusler B; Perret C; Rogers-Evans M; Kimbara A; Nettekoven M; Guba W; Grether U; Ullmer C; Kelly MEM
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31540271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research progress on natural cannabinoid receptor type 2( CB2R)regulators and their effects on bone metabolism].
    Hu SJ; Lian CX; Yu T; Zahng Q; Zhang QL; Zhang QY; Qin LP
    Zhongguo Zhong Yao Za Zhi; 2021 Jul; 46(14):3540-3550. PubMed ID: 34402276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endocannabinoid system: physiology and pharmacology.
    Rodríguez de Fonseca F; Del Arco I; Bermudez-Silva FJ; Bilbao A; Cippitelli A; Navarro M
    Alcohol Alcohol; 2005; 40(1):2-14. PubMed ID: 15550444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional CB2 type cannabinoid receptors at CNS synapses.
    Morgan NH; Stanford IM; Woodhall GL
    Neuropharmacology; 2009 Sep; 57(4):356-68. PubMed ID: 19616018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R).
    Graziano G; Delre P; Carofiglio F; Brea J; Ligresti A; Kostrzewa M; Riganti C; Gioè-Gallo C; Majellaro M; Nicolotti O; Colabufo NA; Abate C; Loza MI; Sotelo E; Mangiatordi GF; Contino M; Stefanachi A; Leonetti F
    Eur J Med Chem; 2023 Feb; 248():115109. PubMed ID: 36657299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
    Sharir H; Console-Bram L; Mundy C; Popoff SN; Kapur A; Abood ME
    J Neuroimmune Pharmacol; 2012 Dec; 7(4):856-65. PubMed ID: 22454039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?
    Gonçalves ED; Dutra RC
    Drug Discov Today; 2019 Sep; 24(9):1845-1853. PubMed ID: 31158514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The progress of small molecules against cannabinoid 2 receptor (CB
    Zhang Q; Zhao Y; Wu J; Zhong W; Huang W; Pan Y
    Bioorg Chem; 2024 Mar; 144():107075. PubMed ID: 38218067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neuropharmacology of cannabinoid receptor ligands in central signaling pathways.
    Brunt TM; Bossong MG
    Eur J Neurosci; 2022 Feb; 55(4):909-921. PubMed ID: 32974975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of type 2 cannabinoid receptor (CB2R) by selective agonists regulates the deposition and remodelling of the extracellular matrix.
    Guan T; Zhao G; Duan H; Liu Y; Zhao F
    Biomed Pharmacother; 2017 Nov; 95():1704-1709. PubMed ID: 28958132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
    Galaj E; Xi ZX
    CNS Drugs; 2019 Oct; 33(10):1001-1030. PubMed ID: 31549358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological potential of JWH133, a cannabinoid type 2 receptor agonist in neurodegenerative, neurodevelopmental and neuropsychiatric diseases.
    Hashiesh HM; Jha NK; Sharma C; Gupta PK; Jha SK; Patil CR; Goyal SN; Ojha SK
    Eur J Pharmacol; 2021 Oct; 909():174398. PubMed ID: 34332924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.